Naimish Patel

Naimish Patel is a declared insider of CRISPR Therapeutics AG, with filings sourced from SEC (Form 4). The record holds 7 filings, for trades running from 3 April 2025 to 29 May 2026.

Both buying and selling appear: 1 purchase worth €45k, against 3 sales worth €438k. On balance, insiders were net sellers of €393k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 3 option exercises. 2026 to date brings 1 purchase and 2 sales.

The record was last updated on 1 June 2026 with an option exercise in CRISPR Therapeutics AG. The most recent open-market purchase was published on 27 January 2026, 270 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.